Wrap Text
Renergen Announces Helium Powered Transport Solution For Vaccines
RENERGEN LIMITED
Incorporated in the Republic of South Africa
(Registration number: 2014/195093/06)
JSE Share code: REN
A2X Share code: REN
ISIN: ZAE000202610
LEI: 378900B1512179F35A69
Australian Business Number (ABN): 93 998 352 675
ASX Share code: RLT
(“Renergen” or “the Company”)
RENERGEN ANNOUNCES HELIUM POWERED TRANSPORT SOLUTION FOR VACCINES
Emerging domestic natural gas and helium producer Renergen has developed a ground-breaking
device, named Renergen Cryo-Vacc, which will simplify logistics of moving vaccines at
temperatures of between -70 and -150 Celsius for periods of up to 30 days, without the need for
any power supply. The company has filed for the patent rights to its design (patent application
number 2020/07629) and is calling on collaborators to use the design in the large-scale
manufacture of these devices, to assist in the deployment of ultra-low temperature vaccines, such
as the recently announced Pfizer COVID-19 vaccine.
The Renergen Cryo-Vacc has been initially designed to transport a minimum of 100 doses, whilst
keeping the vaccine at the required cooling rate of -70 degrees Celsius. Importantly, by utilising
the Renergen Cryo-Vacc, vaccines and biologics can be transported for up to 30 days, regardless
of ambient conditions. This simplifies the logistics significantly and means the vaccines are able
to be transported using traditional logistics chains.
The Renergen Cryo-Vacc device will be constructed of aluminium, providing durability and a long
lifespan for end users. A reservoir has been built into the device, which is filled with liquid helium,
the coldest liquid available globally. This is then boiled and released over a 30-day period to
maintain the temperature at a constant level. Liquid helium is also 20% of the density of liquid
nitrogen, making the device light enough to carry, with an overall weight of less than 20kg.
Commenting on the development of the Renergen Cryo-Vacc, Managing Director and Chief
Executive Officer Stefano Marani said “At first, we attempted to find a solution using liquid
nitrogen given it is significantly cheaper, but you only had four days to get the payload to its
destination for the same weight. It became very clear that for delivery into remote areas and
developing economies, helium was the only solution for the Renergen Cryo-Vacc. Fortunately,
given helium’s specific heat characteristics, it simplified the design substantially and will make
the manufacture of the devices not only quicker but more cost-effective.
“As an emerging helium producer, we are proud to have developed this innovative concept, at a
time when the world is seeking solutions on how to overcome the COVID-19 pandemic. Defeating
it will take collaboration. For that reason we are inviting partners with the resources to roll-out
large-scale manufacture of the Renergen Cryo-Vacc and global logistics companies who are able
to transportation medical supplies. Importantly, with the devices in circulation, transportation can
be completed in a cost-effective manner, given the relatively small size and weight of the devices.
Depending on where the helium is sourced, the operating cost of the device should be under
US$0.07 per dose per day for the smallest device.”
The device works to transport vaccines with liquid nitrogen too, but the vaccines must reach their
intended destination within four days, unless the user is willing to increase the weight by an
additional 15kg, which could stretch the timeline to around 20 days, but at significantly higher air-
freight costs.
An explanatory video of the device may be seen at this link: https://www.renergen.co.za/cryo-
vacc/
Johannesburg
10 December 2020
Authorised by: Stefano Marani
Chief Executive Officer
Designated Advisor
PSG Capital
To readers reviewing this announcement on the Stock Exchange News Service (SENS), this
announcement may contain graphics and/or images which can be found in the PDF version
posted on the Company’s website.
To readers reviewing this announcement who wish to find out more about LNG, watch our LNG
video, which is posted on the Company’s website https://www.renergen.co.za/videos/
For South African investor inquiries, contact Renergen
info@renergen.co.za
+2710 045 6007
For South African media enquiries, contact OwnAlchemy
Michael Rubenstein
+2782 903 7797
michael@ownalchemy.com
For Australian Investors & Media, contact Citadel-MAGNUS
Cameron Gilenko
0466 984 953
About Renergen
Renergen is an emerging producer of helium and liquefied natural gas (LNG), with existing
production and sales of gas to buses in the Free State. Renergen was listed on Johannesburg’s
AltX securities exchange in June 2015 as South Africa’s first listed alternative and renewable
energy company. Renergen listed on the Australian Securities Exchange (ASX) on the 6th June
2019, with the code RLT. Renergen’s principal asset is its 100% shareholding in Tetra4, which
holds the first and only onshore petroleum production right in South Africa, giving it first mover
advantage on distribution of domestic natural gas, along with the potential to become one of the
major global helium suppliers, making South Africa only the 8th country in the world to export this
extremely rare gas.
www.renergen.co.za
Date: 10-12-2020 08:05:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
